ClinicalTrials.gg
Active, not recruitingNCT07104513RLRLUpdated Sep 8, 2025

Efficacy and Influencing Factors of Repeated Low-level Red-light in Myopia

An observational study in Myopia, sponsored by Ruihua Wei. Active, not recruiting at 2 sites in China. Open to participants aged 5 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Ruihua Wei · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,000
Ages
5 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 220 studies in Myopia with a site in China — 81 open to participants now, 101 under way, 4 of them phase 3. Myopia · China.

Planned enrollment
21st of 66
3,000 · median 1,000
Started
2020
with 18 others
Observational
66 of 220
22 open now
Primary completion
2028-07
later than 91 of 100 live
Registered
175th of 220
by date
Lead sponsor
5 of 220
Ruihua Wei

Among the 220 studies in Myopia with a site in China, this one is the 21st largest by planned enrollment of the 66 observational ones that give a count, is one of 19 that started in 2020, is one of 66 observational ones, reaches primary completion later than 91 of the 100 other live ones, and was the 175th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

81 of the 220 studies in Myopia with a site in China are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 5 Years to 16 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Myopia with a site in China, or all of them as a file.
02

Study summary

To evaluate the long-term efficacy of repeated low-level red-light (RLRL) therapy in the prevention and control of myopia in children, and to analyze the key factors influencing its efficacy (such as individual differences and compliance), with the aim of providing evidence-based support for the optimization of clinical myopia prevention and control strategies.

Read the detailed description

This is a real world multi-centre study. The devices are connected to the internet with an automated diary function to record treatment sessions and to monitor patient compliance.The total sample size of 3000 arerandomly allocated into treatment groups,observation for 1 year and more.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
5 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

5-16 years old, 500

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 5 to 16, gender unrestricted;
  2. RLRL device usage duration of one year or more.

Exclusion criteria

Exclusion Criteria:

  • Children with obvious strabismus and amblyopia
  • With congenital eye disease, such as congenital cataract, congenital retinal disease
  • Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
  • Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
  • Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
  • Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP >21mmHg or binocular IOP difference ≥5mmHg)
  • Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
  • Optic nerve damage or congenital optic nerve dysfunction
  • Can not be regularly checked
  • The adjustment range is less than 8D or obvious near difficulties
  • Other reasons researchers think it is not suitable for inclusion in researchers
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • The RLRL-1year Group

    use red light 1 year

    Device: Red Light

  • The RLRL-2years Group

    Device: Red Light

  • The RLRL-3years Group

    Device: Red Light

  • The RLRL-more than 3 years

    use the RLRL-more than 3 years

    Device: Red Light

Interventions

  • DeviceRed Light

    use red light twice per day, both eyes. use red light for one year in The RLRL-1year Group. use red light for two year in The RLRL-2years Group. red light for three years in The RLRL-3years Group.red light for more than three years in The RLRL- more than 3years Group.

06

What researchers measure

Primary outcomes

  1. axial length

    Time frame: up to 72 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Jul 2028, 94 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 5, 2025
StartActual
Sep 28, 2020
Primary completionEst.
Jul 28, 2028
CompletionEst.
Jul 28, 2030
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07104513
Lead sponsor
Ruihua Wei
Responsible party
Ruihua Wei (Professor, Tianjin Medical University Eye Hospital) — Sponsor-investigator
First posted
Aug 5, 2025
Start date
Sep 28, 2020
Primary completion
Jul 28, 2028 (estimated)
Completion
Jul 28, 2030 (estimated)
Last update
Sep 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion